Abstract:Background: Dual-layer spectral computed tomography (DSCT) is capable of acquiring both conventional and spectral images during one routine scan, and is widely used for the quantitative and qualitative analyses of substances, differential diagnosis, and disease staging. However, limited research has been conducted on its performance in the differential diagnosis of benign and malignant breast nodules using non-enhanced scans. This study aimed to assess the diagnostic performance of multiple quantitative parameters derived from non-enhanced DSCT in differentiating benign from malignant breast nodules. Methods: This retrospective cross-sectional study examined a total of 121 breast nodules from 114 patients (malignant group: n=68; benign group: n=53) identified during chest physical examination or routine admission for the treatment of breast diseases at The First Affiliated Hospital of Soochow University from March 2023 to December 2023. All the patients underwent DSCT scanning and pathological diagnosis. The DSCT quantitative parameters, including the effective atomic number (Zeff), computed tomography (CT) attenuation values at 40-70 keV, and the slope of the spectral Hounsfield unit curve (λHU), in non-enhanced images were measured. The λHU was calculated as follows: λHU = CT70 keV - CT40 keV/30 HU. Additionally, typical radiological features were analyzed. A DSCT parameter diagnostic model and a conventional CT diagnostic model were assessed using receiver operating characteristic (ROC) curves. The Delong test was used to assess and compare the diagnostic performance of each model. Results: The DSCT parameters, including the Zeff (P<0.001), λHU (P<0.001), and CT attenuation values at 40 keV (P<0.001) and 50 keV (P=0.001), as well as the presence of the lobular sign (P<0.001) and spicule sign (P<0.001), exhibited statistically significant differences between the benign and malignant groups. The logistic regression analysis revealed that the Zeff [odds ratio (OR): 9.22; 95% confidence interval (CI): 2.11-40.35; P=0.003], λHU (OR: 0.64; 95% CI: 0.52-0.79; P<0.001), 40 keV CT attenuation value (OR: 8.69; 95% CI: 3.28-23.06; P<0.001), 50 keV CT attenuation value (OR: 0.01; 95% CI: 0.001-0.07; P<0.001), and lobular sign (OR: 3.95; 95% CI: 1.52-10.31; P=0.005) were independent predictors of malignancy. Compared to the benign group, the malignant group had a higher likelihood of presenting with the lobular sign and higher Zeff values but lower λHU values. The ROC curve indicated that the Zeff had the highest diagnostic efficacy [area under the curve (AUC) of the ROC =0.792, 95% CI: 0.71-0.87]. Further, the DSCT parameter diagnostic model had improved diagnostic efficacy with an AUC of 0.899 (95% CI: 0.84-0.96), which was higher than the AUC of the conventional CT diagnostic model (AUC =0.796, 95% CI: 0.72-0.87). The Delong test revealed a statistically significant difference between these two models (P=0.04). Conclusions: DSCT parameters derived from non-enhanced DSCT images, such as the Zeff value and λHU, can be used to differentiate benign and malignant breast nodules, and the differential diagnosis efficacy of the DSCT parameters is higher than that of conventional CT parameters.

Correlation between dual-energy spectral CT imaging parameters and pathological grades of non-small cell lung cancer

Diagnostic Value of Spectral CT Parameters in Differentiating Different Types of Lung Cancer

Analysis Of Dual Energy Spectral Ct And Pathological Grading Of Clear Cell Renal Cell Carcinoma (Ccrcc)

The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC

Application of Single-Source Dual-Energy Spectral CT in Differentiating Lymphoma and Metastatic Lymph Nodes in the Head and Neck

[Diagnostic Value of Dual Energy CT for Lymph Node Metastasis in Patients with Non-Small Cell Lung Cancer].

Spectral CT for preoperative diagnosis of N2 station lymph node metastasis in solid T1 non-small cell lung cancer

The value of quantitative analysis with spectral CT imaging in the diagnosis of non-small cell lung cancer with different pathological types

Prediction of histologic grade of hepatocellular carcinoma using dual-layer spectral-detector computed tomography (CT): comparison of two region of interest plotting methods

Value of spectral parameters in the differential diagnosis of benign and malignant breast nodules in non-enhanced chest CT

The application of dual-layer spectral detector computed tomography in solitary pulmonary nodule identification

Spectral CT Imaging Parameters and Ki-67 Labeling Index in Lung Adenocarcinoma

Differentiating peripheral lung cancers from inflammatory masses using dual energy spectral CT imaging

Hepatocellular carcinoma and focal nodular hyperplasia of the liver: differentiation with CT spectral imaging

Is There Any Correlation Between Spectral CT Imaging Parameters and PD‐L1 Expression of Lung Adenocarcinoma?

Can Spectral Computed Tomography (CT) Replace Perfusion CT to Assess the Histological Classification of Non-Small Cell Lung Cancer?

Differential Diagnosis of Hepatic Cancerous Nodules and Cirrhosis Nodules by Spectral CT Imaging: a Feasibility Study

Dual-layer spectral detector computed tomography parameters can improve diagnostic efficiency of lung adenocarcinoma grading

Values of Spectral CT Imaging in Differential Diagnosis of Hepatocellular Carcinoma and Focal Nodular Hyperplasia

Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: Association Between Quantitative Parameters Derived from Dual-Energy CT and Histopathological Prognostic Factors

The value of dual-energy spectral CT in differentiating solitary pulmonary tuberculosis and solitary lung adenocarcinoma